Top

Published in:

01-12-2015 | Original Research

The Impact of Neurofibromatosis Type 1 on the Health and Wellbeing of Australian Adults

Authors: Hilda A. Crawford, Belinda Barton, Meredith J. Wilson, Yemima Berman, Valerie J. McKelvey-Martin, Patrick J. Morrison, Kathryn N. North

Published in: Journal of Genetic Counseling | Issue 6/2015

Abstract

The complications of neurofibromatosis type 1 (NF1) are widespread, unpredictable and variable and each person’s experience of this disorder is unique. However, few studies have addressed the impact of NF1 from an individual’s perspective. This qualitative study aims to identify the ways in which NF1 impacts upon affected Australian adults. Sixty adults with NF1, with a range of disease severity and visibility participated in a semi-structured interview about the ways in which NF1 impacted upon their life and health. Data were analyzed using grounded theory methodology. Results indicated that NF1 impacts upon affected adults in five major ways: 1) cosmetic burden of disease 2) learning difficulties 3) concerns about the risk of passing NF1 to offspring 4) uncertain disease progression, and 5) pain. Participants identified the aspects of NF1 that bothered them the most, creating a hierarchy of NF1 concerns within the cohort. Importantly, mildly affected adults shared many of the same concerns as those more severely affected. This study enhances our current understanding of the impact of NF1 in adulthood, and augments existing recommendations for the care of these patients.

Ablon, J. (1996). Gender response to neurofibromatosis 1. Soc Sci Med, 42(1), 99–110. doi:10.1016/0277-9536(95)00076-3.CrossRefPubMed

Ablon, J. (1999). Living with genetic disorder. The impact of neurofibromatosis 1. Westport: Auburn House.

Agliata, D., & Tantleff-Dunn, S. (2004). The impact of media exposure on males’ body image. J Soc Clin Psychol, 23(1), 7–22. doi:10.1521/jscp.23.1.7.26988.CrossRef

Anon. (1988). Neurofibromatosis. Conference statement. National Institutes of Health consensus development conference. [Neurofibromatosis conference statement National-Institutes-of-Health consensus development conference]. Arch Neurol, 45(5), 575–578.CrossRef

Babrow, A. S., & Kline, K. N. (2000). From “reducing” to “coping with” uncertainty: reconceptualizing the central challenge in breast self-exams. Soc Sci Med, 51(12), 1805–1816. doi:10.1016/s0277-9536(00)00112-x.CrossRefPubMed

Bair, M. J., Robinson, R. L., Katon, W., & Kroenke, K. (2003). Depression and pain comorbidity - A literature review. Arch Intern Med, 163(20), 2433–2445. doi:10.1001/archinte.163.20.2433.CrossRefPubMed

Barke, J., Harcourt, D., & Coad, J. (2014). ‘It’s like a bag of pick and mix—you don’t know what you are going to get’: young people’s experience of neurofibromatosis Type 1. J Adv Nurs, 70(7), 1594–1603. doi:10.1111/jan.12319.CrossRefPubMed

Benjamin, C. M., Colley, A., Donnai, D., Kingston, H., Harris, R., & Kerzinstorrar, L. (1993). Neurofibromatosis type-1 (NF1)—knowledge, experience, and reproductive decisions of affected patients and families. J Med Genet, 30(7), 567–574. doi:10.1136/jmg.30.7.567.PubMedCentralCrossRefPubMed

Brashers, D. E. (2001). Communication and uncertainty management. J Commun, 51(3), 477–497. doi:10.1111/j.1460-2466.2001.tb02892.x.CrossRef

Charmaz, K. (2006). Constructing grounded theory. a practical guide through qualitative analysis. London: Sage.

Chren, M. M. (2010). Interpretation of quality-of-life scores. J Investig Dermatol, 130(5), 1207–1209. doi:10.1038/jid.2010.51.PubMedCentralCrossRefPubMed

Chren, M. M. (2012). The Skindex instruments to measure the effects of skin disease on quality of life. Dermatol Clin, 30(2), 231–236. doi:10.1016/j.det.2011.11.003.PubMedCentralCrossRefPubMed

ClinicalTrials.gov (2012). Acceptance and committment therapy for adolescents and young adults with neurofibromatosis and chronic pain. Retrieved 28 October, 2014, from U.S. National Institutes of Health http://clinicaltrials.gov/show/NCT01633008

Coron, F., Rousseau, T., Jondeau, G., Gautier, E., Binquet, C., Gouya, L., et al. (2012). What do French patients and geneticists think about prenatal and preimplantation diagnoses in Marfan syndrome? Prenat Diagn, 32(13), 1318–1323. doi:10.1002/pd.4008.CrossRefPubMed

Creange, A., Zeller, J., Rostaing-Rigattieri, S., Brugieres, P., Degos, J. D., Revuz, J., et al. (1999). Neurological complications of neurofibromatosis type 1 in adulthood. Brain, 122, 473–481. doi:10.1093/brain/122.3.473.CrossRefPubMed

Evans, D. G., Howard, E., Giblin, C., Clancy, T., Spencer, H., Huson, S. M., et al. (2010). Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK Family Genetic Register service. Am J Med Genet A, 152A(2), 327–332. doi:10.1002/ajmg.a.33139.CrossRefPubMed

Evans, D. G. R., Huson, S. M., & Birch, J. M. (2012). Malignant peripheral nerve sheath tumours in inherited disease. Clinical Sarcoma Research, 2(1), 17. doi:10.1186/2045-3329-2-17.PubMedCentralCrossRefPubMed

Farhi, D., Bastuji-Garin, S., Khosrotchrani, K., Vidaud, D., Bellane, C., Revuz, J., et al. (2008). Neurofibromatosis 1: Analysis of the demand for prenatal diagnosis in a French cohort of 361 patients. Am J Med Genet A, 146A(2), 159–165. doi:10.1002/ajmg.a.32066.CrossRefPubMed

Ferner, R. E. (2007). Neuro-fibromatosis 1 and neuro-fibromatosis 2: a twenty first century perspective. Lancet Neurol, 6(4), 340–351. doi:10.1016/s1474-4422(07)70075-3.CrossRefPubMed

Ferner, R. E. (2010). The neurofibromatoses. Pract Neurol, 10(2), 82–93. doi:10.1136/jnnp.2010.206532.CrossRefPubMed

Ferner, R. E., Hughes, R. A. C., & Weinman, J. (1996). Intellectual impairment in neurofibromatosis 1. J Neurol Sci, 138(1–2), 125–133. doi:10.1016/0022-510x(96)00022-6.CrossRefPubMed

Ferner, R. E., Huson, S. M., Thomas, N., Moss, C., Willshaw, H., Evans, D. G., et al. (2007). Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet, 44(2), 81–88. doi:10.1136/jmg.2006.045906.PubMedCentralCrossRefPubMed

Fildes, J., Robbins, A., Cave, L., Perrens, B., & Wearring, A. (2014). Mission Australia’s 2014 Youth Survey Report. Sydney: Mission Australia.

Granstrom, S., Friedrich, R. E., Langenbruch, A. K., Augustin, M., & Mautner, V. F. (2014). Influence of learning disabilities on the tumour predisposition syndrome NF1-survey from adult patients’ perspective. Anticancer Res, 34(7), 3675–3681.PubMed

Hummelvoll, G., & Antonsen, K. M. (2013). Young adults’ experience of living with neurofibromatosis type 1. J Genet Couns, 22(2), 188–199. doi:10.1007/s10897-012-9527-5.CrossRefPubMed

Huson, S. M., Harper, P. S., & Compston, D. A. S. (1988). Von Recklinghausen neurofibromatosis—a clinical and population study in southeast Wales. Brain, 111, 1355–1381. doi:10.1093/brain/111.6.1355.CrossRefPubMed

Hyman, S. L., Shores, A., & North, K. N. (2005). The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology, 65(7), 1037–1044. doi:10.1212/01.wnl.0000179303.72345.ce.CrossRefPubMed

Jett, K., & Friedman, J. M. (2010). Clinical and genetic aspects of neurofibromatosis 1. Genetics in Medicine, 12(1), 1–11. doi:10.1097/GIM.0b013e3181bf15e3.CrossRefPubMed

Kodra, Y., Giustini, S., Divona, L., Porciello, R., Calvieri, S., Wolkenstein, P., et al. (2009). Health-related quality of life in patients with neurofibromatosis type 1. Dermatology, 218(3), 215–220. doi:10.1159/000187594.CrossRefPubMed

Korf, B., & Rubenstein, A. E. (2005). Neurofibromatosis a handbook for patients, families, and health care professionals (2nd ed.). NY: Thieme.

Krueger, G., Koo, J., Lebwohl, M., Menter, A., Stern, R. S., & Rolstad, T. (2001). The impact of psoriasis on quality of life—results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol, 137(3), 280–284.PubMed

Lasek, R. J., & Chren, M. M. (1998). Acne vulgaris and the quality of life of adult dermatology patients. Arch Dermatol, 134(4), 454–458. doi:10.1001/archderm.134.4.454.CrossRefPubMed

Lehtonen, A., Howie, E., Trump, D., & Huson, S. M. (2013). Behaviour in children with neurofibromatosis type 1: cognition, executive function, attention, emotion, and social competence. Dev Med Child Neurol, 55(2), 111–125. doi:10.1111/j.1469-8749.2012.04399.x.CrossRefPubMed

Mauger, D., Zeller, J., Revuz, J., & Wolkenstein, P. (1999). Psychological impact of neurofibromatosis type I: analysis of interviews with 12 patients to evaluate quality of life. Annales De Dermatologie Et De Venereologie, 126(8–9), 619–620.PubMed

Mautner, V. F., Granstrom, S., & Leark, R. A. (2012). Impact of ADHD in adults with neurofibromatosis type 1: associated psychological and social problems. J Atten Disord, XX(X), 1–9.

Montgomery, P., & Bailey, P. H. (2007). Field notes and theoretical memos in grounded theory. West J Nurs Res, 29(1), 65–79. doi:10.1177/0193945906292557.CrossRefPubMed

Oates, E. C., Payne, J. M., Foster, S. L., Clarke, N. F., & North, K. N. (2013). Young Australian adults with NF1 have poor access to health care, high complication rates, and limited disease knowledge. Am J Med Genet A, 161A(4), 659–666. doi:10.1002/ajmg.a.35840.CrossRefPubMed

Odonnell, B. F., Lawlor, F., Simpson, J., Morgan, M., & Greaves, M. W. (1997). The impact of chronic urticaria on the quality of life. Br J Dermatol, 136(2), 197–201.CrossRef

Page, P. Z., Korf, B. R., Page, G. P., Leplege, A., & Wolkenstein, P. (2004). Quality of life in adults with neurofibromatosis type 1. Genetics in Medicine, 6(4), 346.

Pride, N. A., & North, K. N. (2012). The cognitive profile of NF1 children: therapeutic implications. In M. Upadhhyaya & D. N. Cooper (Eds.), Neurofibromatosis Type 1 Molecular and Cellular Biology (pp. 55–70). Heidelberg: Springer.CrossRef

Pride, N. A., Payne, J. M., & North, K. N. (2012). The impact of ADHD on the cognitive and academic functioning of children with nf1. Dev Neuropsychol, 37(7), 590–600. doi:10.1080/87565641.2012.695831.CrossRefPubMed

Pride, N. A., Crawford, H., Payne, J. M., & North, K. N. (2013). Social functioning in adults with neurofibromatosis type 1. Res Dev Disabil, 34(10), 3393–3399. doi:10.1016/j.ridd.2013.07.011.CrossRefPubMed

Radtke, H. B., Sebold, C. D., Allison, C., Haidle, J. L., & Schneider, G. (2007). Neurofibromatosis type 1 in genetic counseling practice: recommendations of the National Society of Genetic Counselors. J Genet Couns, 16(4), 387–407. doi:10.1007/s10897-007-9101-8.CrossRefPubMed

Reichardt, C., Scherwath, A., Mautner, V. F., Bullinger, M., & Petersen-Ewert, C. (2013). Psychological distress in adults with neurofibromatosis type 1: a longitudinal study. Psychother Psychosom Med Psychol, 63(2), 85–92. doi:10.1055/s-0032-1321883.CrossRefPubMed

Riccardi, V. M., & Kleiner, B. (1977). Neurofibromatosis: a neoplastic birth defect with two age peaks of severe problems. Birth Defects Original Article Series, 13(3C), 131–138.PubMed

Rieley, M. B., Stevenson, D. A., Viskochil, D. H., Tinkle, B. T., Martin, L. J., & Schorry, E. K. (2011). Variable expression of neurofibromatosis 1 in monozygotic twins. Am J Med Genet A, 155A(3), 478–485. doi:10.1002/ajmg.a.33851.CrossRefPubMed

Rumsey, N., & Harcourt, D. (2004). Body image and disfigurement: issues and interventions. Body Image, 1(1), 83–97. doi:10.1016/s1740-1445(03)00005-6.CrossRefPubMed

Sabbagh, A., Pasmant, E., Laurendeau, I., Parfait, B., Barbarot, S., Guillot, B., et al. (2009). Unravelling the genetic basis of variable clinical expression in neurofibromatosis 1. Hum Mol Genet, 18(15), 2768–2778. doi:10.1093/hmg/ddp212.PubMedCentralCrossRefPubMed

Samuelsson, B., & Axelsson, R. (1981). Neurofibromatosis - a clinical and genetic-study of 96 cases in Gothenburg, Sweden. Acta Dermato-Venereologica, 67–71.

Sarwer, D. B., Bartlett, S. P., Whitaker, L. A., Paige, K. T., Pertschuk, M. J., & Wadden, T. A. (1999). Adult psychological functioning of individuals born with craniofacial anomalies. Plast Reconstr Surg, 103(2), 412–418. doi:10.1097/00006534-199902000-00008.

Sbaraini, A., Carter, S. M., Evans, R. W., & Blinkhorn, A. (2011). How to do a grounded theory study: a worked example of a study of dental practices. Bmc Medical Research Methodology, 11. doi:10.1186/1471-2288-11-128

Shannon, M. L., & Stark, C. P. (2003). The influence of physical appearance on personnel selection. Social Behavior and Personality, 31(6), 613–623.CrossRef

Sharif, S., Moran, A., Huson, S. M., Iddenden, R., Shenton, A., Howard, E., et al. (2007). Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. J Med Genet, 44(8), 481–484. doi:10.1136/jmg.2007.049346.PubMedCentralCrossRefPubMed

Skirton, H., & Bylund, C. L. (2010). Management of uncertainty. In C. L. Gaff & C. L. Bylund (Eds.), Family Communication about Genetics Theory and Practice (pp. 136–151). New York: Oxford University Press.

Smith, K. B., Wang, D. L., Plotkin, S. R., & Park, E. R. (2013). Appearance concerns among women with neurofibromatosis: examining sexual/bodily and social self-consciousness. Psycho-Oncology, 22(12), 2711–2719. doi:10.1002/pon.3350.CrossRefPubMed

Sorensen, S. A., Mulvihill, J. J., & Nielsen, A. (1986). On the natural-history of Von Recklinghausen neurofibromatosis. Ann N Y Acad Sci, 486, 30–37.CrossRefPubMed

Terzi, Y. K., Oguzkan-Balci, S., Anlar, B., Aysun, S., Guran, S., & Ayter, S. (2009). Reproductive decisions after prenatal diagnosis in neurofibromatosis type 1: importance of genetic counseling. Genet Couns, 20(2), 195–202.PubMed

Tews, M. J., Stafford, K., & Zhu, J. F. (2009). Beauty revisited: the impact of attractiveness, ability, and personality in the assessment of employment suitability. Int J Sel Assess, 17(1), 92–100. doi:10.1111/j.1468-2389.2009.00454.x.CrossRef

Thompson, A., & Kent, G. (2001). Adjusting to disfigurement: Processes involved in dealing with being visibly different. Clin Psychol Rev, 21(5), 663–682. doi:10.1016/s0272-7358(00)00056-8.CrossRefPubMed

Wang, D. L., Smith, K. B., Esparza, S., Leigh, F. A., Muzikansky, A., Park, E. R., et al. (2012). Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome. Genetics in Medicine, 14(12), 977–982. doi:10.1038/gim.2012.85.PubMedCentralCrossRefPubMed

Wolkenstein, P., Zeller, J., Revuz, J., Ecosse, E., & Leplege, A. (2001). Quality-of-life impairment in neurofibromatosis type 1—A cross-sectional study of 128 cases. Arch Dermatol, 137(11), 1421–1425.CrossRefPubMed

World Med Association. (2013). World Medical Association Declaration of Helsinki ethical principles for medical research involving human subjects. Jama-Journal of the American Medical Association, 310(20), 2191–2194. doi:10.1001/jama.2013.281053.CrossRef

Title: The Impact of Neurofibromatosis Type 1 on the Health and Wellbeing of Australian Adults
Authors: Hilda A. Crawford
Belinda Barton
Meredith J. Wilson
Yemima Berman
Valerie J. McKelvey-Martin
Patrick J. Morrison
Kathryn N. North
Publication date: 01-12-2015
Publisher: Springer US
Published in: Journal of Genetic Counseling / Issue 6/2015
Print ISSN: 1059-7700
Electronic ISSN: 1573-3599
DOI: https://doi.org/10.1007/s10897-015-9829-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Impact of Neurofibromatosis Type 1 on the Health and Wellbeing of Australian Adults

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2015

Psychosocial Responses to being Identified as a Balanced Chromosomal Translocation Carrier: a Qualitative Investigation of Parents in Japan

Assessing Parental Knowledge About Thalassemia in a Thalassemia Center of Karachi, Pakistan

Facilitators and Challenges in Psychosocial Adaptation to Being at Increased Familial Risk of Breast Cancer

Presented Abstracts from the Thirty Fourth Annual Education Conference of the National Society of Genetic Counselors (Pittsburgh, PA, October 2015)

“Suddenly Having two Positive People who are Carriers is a Whole New Thing”- Experiences of Couples Both Identified as Carriers of Cystic Fibrosis Through a Population-Based Carrier Screening Program in Australia

Using ApoE Genotyping to Promote Healthy Lifestyles in Finland – Psychological Impacts: Randomized Controlled Trial